Tamoxifen Fails to Show Efficacy in Duchenne Patients in Phase 3 Trial

Tamoxifen Fails to Show Efficacy in Duchenne Patients in Phase 3 Trial

308921

Tamoxifen Fails to Show Efficacy in Duchenne Patients in Phase 3 Trial

Tamoxifen, commonly used to treat breast cancer, failed to meet its primary goal — delaying disease progression — in a Phase 3 study evaluating its use in boys with Duchenne muscular dystrophy (DMD), preliminary data show. Boys treated with tamoxifen and those given a placebo over 48 weeks in the TAM-DMD trial (NCT03354039) showed mild disease progression. A trend toward slower progression was seen in boys on tamoxifen, but early data indicated that group differences were…

You must be logged in to read/download the full post.